VAERS ID: 2331194

AGE: | SEX: U|STATE: FR

Description

five residents infected after prime vaccination were excluded in the study; five residents infected after prime vaccination were excluded in the study; This is a literature report for the following literature source(s): An elderly patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "five residents infected after prime vaccination were excluded in the study". The patient underwent the following laboratory tests and procedures: Blood immunoglobulin G: Unknown results; Unknown results; Unknown results; Unknown results; SARS-CoV-2 IgG assay: Unknown results; Unknown results; SARS-CoV-2 antibody test: Unknown results. Authors have read with great interest the recent article showing that vaccine effectiveness against Covid-19 during an outbreak in a nursing home (NH) correlates with anti-Spike IgG. In this study, anti-Spike IgG below 50 BAU/mL 28 weeks after two vaccine doses resulted in a higher risk of SARS-CoV-2 infection and severe form of the disease. In this study performed between March and October 2021, compare the response to BNT162b2 vaccine in NH residents depending on their age, 95 years or older vs less than 95 years of age, and their history of prior SARS-CoV-2 infection. A total of 412 NH residents were tested at the 3 time points. Five residents infected after the prime vaccination were excluded.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of the reported events cannot be totally excluded. ,Linked Report(s) : FR-PFIZER INC-202200853526 Same article/ drug/event and different patient.;

Symptoms

Blood immunoglobulin G, COVID-19, Drug ineffective, Investigation, SARS-CoV-2 antibody test

Vaccines

VAX DATE: | ONSET DATE: | DAYS TO ONSET:
NameDose #TypeManufacturerLotRouteSite
COVID19 (COVID19 (PFIZER-BIONTECH)) 2 COVID19 PFIZER\BIONTECH Unknown Unknown

RECVDATE:06-24-2022
RPT_DATE:
CAGE_YR:
CAGE_MO:
DIED:U
DATEDIED:
L_THREAT:U
ER_VISIT:U
HOSPITAL:U
HOSPDAYS:
X_STAY:U
DISABLE:U
RECOVD:U
LAB_DATA:Test Name: anti-Spike IgG; Result Unstructured Data: Test Result:Unknown results; Test Name: nucleocapsid-IgG; Result Unstructured Data: Test Result:Unknown results; Test Name: Nucleoprotein-IgG; Result Unstructured Data: Test Result:Unknown results; Test Name: RBD-IgG; Result Unstructured Data: Test Result:Unknown results; Test Name: SARS-CoV-2 IgG assay; Result Unstructured Data: Test Result:Unknown results; Test Name: SARS-CoV-2 IgG II Quant assay; Result Unstructured Data: Test Result:Unknown results; Test Name: SARS-CoV-2 Receptor-Binding Domain (RBD); Result Unstructured Data: Test Result:Unknown results
V_ADMINBY:OTH
OTHER_MEDS:
CUR_ILL:
HISTORY:
PRIOR_VAX:
SPLTTYPE:FRPFIZER INC202200862483
FORM_VERS:2
TODAYS_DATE:06-23-2022
BIRTH_DEFECT:U
OFC_VISIT:U
ER_ED_VISIT:U
ALLERGIES:
V_FUNDBY:

Questions? Comments? Bugs?
[email protected]
Due to the high volume of inquiries, please be patient with response times.

AND PLEASE read the FAQ first.

OpenVAERS is a private organization that posts publicly available CDC/FDA data of injuries reported post-vaccination. Reports are not proof of causality.